Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate | Avenzo Therapeutics
Rgenta Therapeutics Receives Orphan Drug Designation from the U.S. FDA for RGT-61159 for the Treatment of Adenoid Cystic Carcinoma (ACC)
Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy
Cardurion Pharmaceuticals Completes Enrollment in Phase 2 CYCLE Trials Evaluating CRD‑750, a Novel PDE9 inhibitor, in Heart Failure
Imperative Care Secures FDA Clearance and Initial Cases of the Zoom 7X Catheter, the Newest Innovation in Ischemic Stroke Treatment
Sirius Therapeutics Receives European Medicines Agency (EMA) Authorization to Initiate a Phase 2 Clinical Trial of SRSD107 for Thromboembolic Disorders
Imperative Care Presents Positive Imperative Trial Data from Patients Treated with Aspiration Thrombectomy for M2 Occlusions Using the Zoom System
AltruBio Presents New Preclinical Data at FOCIS 2025 Demonstrating ALTB-268’s Efficacy in T Cell-Mediated Inflammatory Models
Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China
